ESMO/LinkedIn
May 16, 2025, 17:20
Two Studies Presented at ESMO Breast 25 Highlight the Potential Benefits of Tailoring Chemotherapy
ESMO – European Society for Medical Oncology shared on LinkedIn:
“Two studies presented at ESMO Breast 25 highlight the potential benefits of tailoring chemotherapy, and even with holding chemotherapy, in some subgroups of patients with early-stage ER+/HER2– Breast Cancer.
The ADAPT cycle phase III Clinical Trial comparing ribociclib plus endocrine therapy versus chemotherapy reported similar pCR rates in the two arms and determined factors that might be informative to guide treatment choice.
A further study (OPTIMA prelim, part of an ongoing OPTMA trial) provided support for a gene expression-based multiparameter assay (MPA) to guide chemotherapy use. Invasive Breast Cancer-free survival rates at 10 years were similar in patients who received standard chemotherapy with endocrine therapy and those who received MPA-directed therapy.
Read the full commentary in the ESMO Daily Reporter.”
More posts featuring ESMO Breast 25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 16:47
May 16, 2025, 16:35
May 16, 2025, 16:18